High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard
Dutcher, J.P.
Oncology 25(5): 427-428
2011
ISSN/ISBN: 0890-9091 PMID: 21710841 Document Number: 654808
Document emailed within 1 workday
Related Documents
Lissoni, P.; Rovelli, F.; Baiocco, N.; Tangini, G.; Fumagalli, L. 2001: A phase Ii study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone Anticancer Research 21(1b): 777-779Lee, D.S.; White, D.E.; Hurst, R.; Rosenberg, S.A.; Yang, J.C. 1998: Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy Cancer Journal From Scientific American 4(2): 86-93
Sznol, M.; Clark, J.W.; Smith, J.W.; Steis, R.G.; Urba, W.J.; Rubinstein, L.V.; VanderMolen, L.A.; Janik, J.; Sharfman, W.H.; Fenton, R.G. 1992: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma Journal of the National Cancer Institute 84(12): 929-937
Proebstle, T.M.; Scheibenbogen, C.; Sterry, W.; Keilholz, U. 1996: A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma European Journal of Cancer 32a(9): 1530-1533
He, C.; Qin, C.; Xu, T.; Yuan, Y.; Liu, Z.; Sheng, Z.; Hu, F.; Dun, Y.; Wang, X. 2015: Expression of glycoprotein non-metastatic melanoma protein B in clear-cell renal cell carcinoma and clinical implication thereof Zhonghua Yi Xue Za Zhi 95(30): 2455-2458
Negrier, S.; Maral, J.; Drevon, M.; Vinke, J.; Escudier, B.; Philip, T. 2000: Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe Cancer Journal from Scientific American 6(Suppl): S93-S98
Bukowski, R.M.; Sharfman, W.; Murthy, S.; Rayman, P.; Tubbs, R.; Alexander, J.; Budd, G.T.; Sergi, J.S.; Bauer, L.; Gibson, V. 1991: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma Cancer Research 51(16): 4199-4205
Cutuli, B.F.; Methlin, A.; Teissier, E.; Schumacher, C.; Jung, G.M. 1990: Radiation therapy in the treatment of metastatic renal-cell carcinoma Progress in Clinical and Biological Research 348: 179-186
Quesada, J.R. 1988: Biologic response modifiers in the therapy of metastatic renal cell carcinoma Seminars in Oncology 15(4): 396-407
Nakano, E. 1992: Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma Hinyokika Kiyo. Acta Urologica Japonica 38(11): 1305-1309
Hofmockel, G.; Wirth, M.P.; Heimbach, D.; Frohmüller, H.G. 1993: Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma Der Urologe. Ausg. a 32(4): 290-294
Fisher, R.I.; Rosenberg, S.A.; Fyfe, G. 2000: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer Journal from Scientific American 6(Suppl): S55-S57
Katakkar, S.B.; Franks, C.R. 1978: Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate Cancer Treatment Reports 62(9): 1379-1380
2015: Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC) Annals of the Academy of Medicine Singapore 44(10): 406-414
Sarma, D.P. 1980: Metastatic basal cell carcinoma: electron microscopic study of the primary and the metastatic lesion Southern Medical Journal 73(6): 799-801
Bearman, S.I.; Shpall, E.J.; Jones, R.B.; Cagnoni, P.J.; Ross, M. 1996: High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer Seminars in Oncology 23(1 Suppl 2: 60-67
Jurincic-Winkler, C.; Horlbeck, R.; Klippel, K.F. 1993: Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer Wiener Klinische Wochenschrift 105(10): 271-276
Royal, R.E.; Steinberg, S.M.; Krouse, R.S.; Heywood, G.; White, D.E.; Hwu, P.; Marincola, F.M.; Parkinson, D.R.; Schwartzentruber, D.J.; Topalian, S.L.; Yang, J.C.; Rosenberg, S.A. 1996: Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma Cancer Journal from Scientific American 2(2): 91-98
Sarma, D.P.; Wang, J.F.; McAllister, M.V.; Wang, B.; Shehan, J.M. 2008: Possible implantation carcinoma of the scalp following craniotomy for metastatic renal cell carcinoma Dermatology Online Journal 14(6): 20
Coşkun, F.; Cetinkaya, M.; Cengiz, O.; Adsan, O.; Kulaçoğlu, S.; Eroğlu, A. 1995: Metastatic carcinoma of the gallbladder due to renal cell carcinoma in the ectopic kidney Acta Chirurgica Belgica 95(1): 56-58